The special dinner lecture focused on detecting inhibitors in VWD, a difficult

area. Finally, we reviewed the topic of women with VWD and controversies in diagnosis and management, and we learnt the importance of a multidisciplinary approach to the care of these patients. We are considering continuing with the Åland islands meetings as a platform to enhance science and collaboration between experts. Writing support was provided by Ros Kenn, freelance medical editor/writer, and funded by Octapharma. Prof. Dr Erik Berntorp (corresponding author) has received speaker honoraria and research support from Octapharma and participated in Advisory boards. Dr Birte Fuchs is an employee of Octapharma, Germany. Dr Mike Makris has acted as a consultant for CSL Behring and selleck chemical Octapharma. He is the coordinator of the EUHASS project which has received funding from Bayer, Baxter, Biotest, CSL Behring, Grifols, LFB, NovoNordisk, Octapharma and see more Pfizer. Dr Makris is not an employee of any pharmaceutical company, does not own stocks or shares in any and does not own any patents. Prof. Dr Robert Montgomery has received

consultancy fees from GTI Diagnostics/Gen-Probe/Hologics, Baxter, Biogen/IDEC, Bayer, Octapharma and CSL Behring. Asst Prof. Dr Veronica Flood has no conflicts of interest to declare. Prof. James S. O’Donnell has served on the speaker’s bureau for Baxter, Bayer, Novo Nordisk, Leo Pharma and Octapharma. He has also served on the advisory boards of Baxter,

Bayer, Octapharma and Pfizer. He has also received research grant funding awards from Baxter, Bayer and Novo Nordisk. Prof. Dr Augusto B. Federici has received consulting fees (e.g., advisory check details boards) from: Baxter Healthcare, CSL Behring, Grifols, Laboratoires Français de Fractionnement et des Biotechnologies (LFB) and Octapharma. Prof. Dr David Lillicrap has received research funding from Bayer, Baxter, CSL and Biogen-Idec. Dr Paula James has received research funding from CSL Behring, and honoraria from CSL Behring, Baxter and Bayer. Prof. Ulrich Budde has no conflicts of interest to declare. Dr Massimo Morfini has acted as a paid consultant to Bayer, Baxter, Novo Nordisk, Pfizer Advisory Boards and received a fee as invited speaker from Bayer, Novo Nordisk, CSL Behring Symposia and Octapharma. Dr Pia Petrini has no conflicts of interest to declare. Dr Steve Austin has received travel grants from Octapharma, Baxter and Pfizer and speakers’ grants from Octapharma and Bayer. He has been on advisory boards for Baxter and Pfizer. Dr Christoph Kannicht is an employee of Octapharma, Germany. Dr Victor Jiménez-Yuste has received fees for speaking from Octapharma, Grifols, NovoNordisk, Pfizer and has participated in advisory boards sponsored by Grifols, Bayer, NovoNordisk, CSL Behring and Pfizer. Prof.